Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Mar 1;4(3):e211031.
doi: 10.1001/jamanetworkopen.2021.1031.

National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016

Christopher T Aquina  1 , Aslam Ejaz  1 , Allan Tsung  1 , Timothy M Pawlik  1 , Jordan M Cloyd  1
Affiliations
Multicenter Study

National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016

Christopher T Aquina et al. JAMA Netw Open. .

Abstract

This cohort study uses information obtained from the US National Cancer Database to evaluate trends in the use of neoadjuvant therapy before tumor resection for various types of cancer from 2004 to 2016.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Trends in the Use of Neoadjuvant Therapy for Various Cancer Types in the US From 2004 to 2016
Figure 2.
Figure 2.. Trends in the Adjusted Odds of Receipt of Neoadjuvant Therapy by Cancer Type in the US From 2004 to 2016
Odds ratios for year of diagnosis were compared with the reference year (2004) after controlling for patient age, sex, race/ethnicity, educational level, income status, insurance type, distance from hospital, Charlson/Deyo Comorbidity Score, tumor grade, American Joint Committee on Cancer Staging Manual, 7th Edition pathologic TNM stage, procedure type, hospital annual organ-specific resection volume, hospital type, and hospital location. Error bars represent 95% CIs.
See this image and copyright information in PMC

References

    1. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. ; CROSS Study Group . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. doi:10.1016/S1470-2045(15)00040-6 - DOI - PubMed
    1. Sauer R, Becker H, Hohenberger W, et al. ; German Rectal Cancer Study Group . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740. doi:10.1056/NEJMoa040694 - DOI - PubMed
    1. Cloyd JM, Heh V, Pawlik TM, et al. . Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129. doi:10.3390/jcm9041129 - DOI - PMC - PubMed
    1. Advanced Bladder Cancer Meta-analysis Collaboration . Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927-1934. doi:10.1016/S0140-6736(03)13580-5 - DOI - PubMed
    1. Boffa DJ, Rosen JE, Mallin K, et al. . Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905 - DOI - PubMed

Publication types

Substances